Skip to main content
NCBI home page
Neurotherapeutics logoLink to Neurotherapeutics
. 2010 Jan;7(1):62–73. doi: 10.1016/j.nurt.2009.11.003

Statins in traumatic brain injury

Elissa F Wible 1, Daniel T Laskowitz 1,2,3,4,✉
PMCID: PMC5084113  PMID: 20129498

Summary

Traumatic brain injury (TBI) is a common cause of long-term neurological morbidity, with devastating personal and societal consequences. At present, no pharmacological intervention clearly improves outcomes, and therefore a compelling unmet clinical need remains. 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, or “statins,” offer a potential novel therapeutic strategy for TBI. Statins are well tolerated, easy to administer, and have a long clinical track record in critically ill patients. Their side effects are well defined and easily monitored. Preclinical studies have shown significant benefit of statins in models of TBI and related disease processes, including cerebral ischemia, intracerebral hemorrhage, and subarachnoid hemorrhage. In fact, multiple mechanisms have been defined by which statins may exert benefit after acute brain injury. Statins are currently positioned to be translated into clinical trials in acute brain injury and have the potential to improve outcomes after TBI.

Key Words: Statin, HMG CoA reductase inhibitor, closed head injury, neuroinflammation, traumatic brain injury

References

  • 1.Rutland-Brown W, Langlois JA, Thomas KE, Xi YL. Incidence of traumatic brain injury in the United States, 2003. J Head Trauma Rehabil. 2006;21:544–548. doi: 10.1097/00001199-200611000-00009. [DOI] [PubMed] [Google Scholar]
  • 2.Langlois JA, Rutland-Brown W, Wald MM. The epidemiology and impact of traumatic brain injury: a brief overview. J Head Trauma Rehabil. 2006;21:375–378. doi: 10.1097/00001199-200609000-00001. [DOI] [PubMed] [Google Scholar]
  • 3.Bulger EM, Nathens AB, Rivara FP, Moore M, MacKenzie EJ, Jurkovich GJ. Management of severe head injury: institutional variations in care and effect on outcome. Crit Care Med. 2002;30:1870–1876. doi: 10.1097/00003246-200208000-00033. [DOI] [PubMed] [Google Scholar]
  • 4.Biros MH, Heegaard W. Prehospital and resuscitative care of the head-injured patient. Curr Opin Crit Care. 2001;7:444–449. doi: 10.1097/00075198-200112000-00012. [DOI] [PubMed] [Google Scholar]
  • 5.McKenney JM. Pharmacologic characteristics of statins. Clin Cardiol. 2003;26:III32–III38. doi: 10.1002/clc.4960261507. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam Clin Pharmacol. 2005;19:117–125. doi: 10.1111/j.1472-8206.2004.00299.x. [DOI] [PubMed] [Google Scholar]
  • 7.Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature. 1990;343:425–430. doi: 10.1038/343425a0. [DOI] [PubMed] [Google Scholar]
  • 8.Cucchiara B, Kasner SE. Use of statins in CNS disorders. J Neurol Sci. 2001;187:81–89. doi: 10.1016/S0022-510X(01)00529-9. [DOI] [PubMed] [Google Scholar]
  • 9.Chen SF, Hung TH, Chen CC, et al. Lovastatin improves histological and functional outcomes and reduces inflammation after experimental traumatic brain injury. Life Sci. 2007;81:288–298. doi: 10.1016/j.lfs.2007.05.023. [DOI] [PubMed] [Google Scholar]
  • 10.Wang H, Lynch JR, Song P, et al. Simvastatin and atorvastatin improve behavioral outcome, reduce hippocampal degeneration, and improve cerebral blood flow after experimental traumatic brain injury. Exp Neurol. 2007;206:59–69. doi: 10.1016/j.expneurol.2007.03.031. [DOI] [PubMed] [Google Scholar]
  • 11.Lu D, Goussev A, Chen J, et al. Atorvastatin reduces neurological deficit and increases synaptogenesis, angiogenesis, and neuronal survival in rats subjected to traumatic brain injury. J Neurotrauma. 2004;21:21–32. doi: 10.1089/089771504772695913. [DOI] [PubMed] [Google Scholar]
  • 12.Lu D, Mahmood A, Qu C, Goussev A, Lu M, Chopp M. Atorvastatin reduction of intracranial hematoma volume in rats subjected to controlled cortical impact. J Neurosurg. 2004;101:822–825. doi: 10.3171/jns.2004.101.5.0822. [DOI] [PubMed] [Google Scholar]
  • 13.Silvestri S, Aronson S. Severe head injury: prehospital and emergency department management. Mt Sinai J Med. 1997;64:329–338. [PubMed] [Google Scholar]
  • 14.Alderson P, Roberts I. Corticosteroids for acute traumatic brain injury. Cochrane Database Syst Rev 2005:CD000196. [DOI] [PMC free article] [PubMed]
  • 15.Ramilo O, Saez-Llorens X, Mertsola J, et al. Tumor necrosis factor alpha/cachectin and interleukin 1 beta initiate meningeal inflammation. J Exp Med. 1990;172:497–507. doi: 10.1084/jem.172.2.497. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Chen G, Zhang S, Shi J, Ai J, Qi M, Hang C. Simvastatin reduces secondary brain injury caused by cortical contusion in rats: possible involvement of TLR4/NF-kappaB pathway. Exp Neurol. 2009;216:398–406. doi: 10.1016/j.expneurol.2008.12.019. [DOI] [PubMed] [Google Scholar]
  • 17.Tsan MF, Gao B. Endogenous ligands of Toll-like receptors. J Leukoc Biol. 2004;76:514–519. doi: 10.1189/jlb.0304127. [DOI] [PubMed] [Google Scholar]
  • 18.Turkoglu OF, Eroglu H, Okutan O, et al. Atorvastatin efficiency after traumatic brain injury in rats. Surg Neurol. 2009;72:146–152. doi: 10.1016/j.surneu.2008.07.004. [DOI] [PubMed] [Google Scholar]
  • 19.Chen XR, Besson VC, Beziaud T, Plotkine M, Marchand-Leroux C. Combination therapy with fenofibrate, a peroxisome proliferator-activated receptor alpha agonist, and simvastatin, a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, on experimental traumatic brain injury. J Pharmacol Exp Ther. 2008;326:966–974. doi: 10.1124/jpet.108.140368. [DOI] [PubMed] [Google Scholar]
  • 20.Ifergan I, Wosik K, Cayrol R, et al. Statins reduce human blood-brain barrier permeability and restrict leukocyte migration: relevance to multiple sclerosis. Ann Neurol. 2006;60:45–55. doi: 10.1002/ana.20875. [DOI] [PubMed] [Google Scholar]
  • 21.Erdos B, Snipes JA, Tulbert CD, Katakam P, Miller AW, Busija DW. Rosuvastatin improves cerebrovascular function in Zucker obese rats by inhibiting NAD(P)H oxidase-dependent Superoxide production. Am J Physiol Heart Circ Physiol. 2006;290:H1264–H1270. doi: 10.1152/ajpheart.00804.2005. [DOI] [PubMed] [Google Scholar]
  • 22.Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) investigators. Circulation. 1999;100:230–235. doi: 10.1161/01.cir.100.3.230. [DOI] [PubMed] [Google Scholar]
  • 23.Gensini GF, Gori AM, Dilaghi B, et al. Effect of atorvastatin on circulating hsCRP concentrations: A sub-study of the Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration (ACTFAST) study. Int J Cardiol 2009 Feb 11. [Epub ahead of print]. [DOI] [PubMed]
  • 24.Ridker PM, Danielson E, Fonseca FA, et al. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet. 2009;373:1175–1182. doi: 10.1016/S0140-6736(09)60447-5. [DOI] [PubMed] [Google Scholar]
  • 25.Tapia-Perez JH, Sanchez-Aguilar M, Torres-Corzo JG, et al. Effect of rosuvastatin on amnesia and disorientation after traumatic brain injury (NCT003229758) J Neurotrauma. 2008;25:1011–1017. doi: 10.1089/neu.2008.0554. [DOI] [PubMed] [Google Scholar]
  • 26.Vink R, Nimmo AJ. Multifunctional drugs for head injury. Neurotherapeutics. 2009;6:28–42. doi: 10.1016/j.nurt.2008.10.036. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Zacco A, Togo J, Spence K, et al. 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors protect cortical neurons from excitotoxicity. J Neurosci. 2003;23:11104–11111. doi: 10.1523/JNEUROSCI.23-35-11104.2003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Ponce J, de la Ossa NP, Hurtado O, et al. Simvastatin reduces the association of NMDA receptors to lipid rafts: a cholesterol-mediated effect in neuroprotection. Stroke. 2008;39:1269–1275. doi: 10.1161/STROKEAHA.107.498923. [DOI] [PubMed] [Google Scholar]
  • 29.Dolga AM, Nijholt IM, Ostroveanu A, Ten Bosch Q, Luiten PG, Eisel UL. Lovastatin induces neuroprotection through tumor necrosis factor receptor 2 signaling pathways. J Alzheimers Dis. 2008;13:111–122. doi: 10.3233/jad-2008-13201. [DOI] [PubMed] [Google Scholar]
  • 30.Lewelt W, Jenkins LW, Miller JD. Autoregulation of cerebral blood flow after experimental fluid percussion injury of the brain. J Neurosurg. 1980;53:500–511. doi: 10.3171/jns.1980.53.4.0500. [DOI] [PubMed] [Google Scholar]
  • 31.Wei EP, Dietrich WD, Povlishock JT, Navari RM, Kontos HA. Functional, morphological, and metabolic abnormalities of the cerebral microcirculation after concussive brain injury in cats. Circ Res. 1980;46:37–47. doi: 10.1161/01.res.46.1.37. [DOI] [PubMed] [Google Scholar]
  • 32.Klauber MR, Marshall LF, Luerssen TG, Frankowski R, Tabaddor K. Eisenberg HM. Determinants of head injury mortality: importance of the low risk patient. Neurosurgery. 1989;24:31–36. doi: 10.1227/00006123-198901000-00005. [DOI] [PubMed] [Google Scholar]
  • 33.Murray GD, Butcher I, McHugh GS, et al. Multivariable prognostic analysis in traumatic brain injury: results from the IMPACT study. J Neurotrauma. 2007;24:329–337. doi: 10.1089/neu.2006.0035. [DOI] [PubMed] [Google Scholar]
  • 34.Williams JK, Sukhova GK, Herrington DM, Libby P. Pravastatin has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeys. J Am Coll Cardiol. 1998;31:684–691. doi: 10.1016/S0735-1097(97)00537-8. [DOI] [PubMed] [Google Scholar]
  • 35.O’Driscoll G, Green D, Taylor RR. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation. 1997;95:1126–1131. doi: 10.1161/01.cir.95.5.1126. [DOI] [PubMed] [Google Scholar]
  • 36.Amin-Hanjani S, Stagliano NE, Yamada M, Huang PL, Liao JK, Moskowitz MA. Mevastatin, an HMG-CoA reductase inhibitor, reduces stroke damage and upregulates endothelial nitric oxide synthase in mice. Stroke. 2001;32:980–986. doi: 10.1161/01.str.32.4.980. [DOI] [PubMed] [Google Scholar]
  • 37.Laufs U, La Fata V, Plutzky J, Liao JK. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation. 1998;97:1129–1135. doi: 10.1161/01.cir.97.12.1129. [DOI] [PubMed] [Google Scholar]
  • 38.Wang H, Durham L, Dawson H, et al. An apolipoprotein E-based therapeutic improves outcome and reduces Alzheimer’s disease pathology following closed head injury: evidence of pharmacogenomic interaction. Neuroscience. 2007;144:1324–1333. doi: 10.1016/j.neuroscience.2006.11.017. [DOI] [PubMed] [Google Scholar]
  • 39.McGirt MJ, Woodworm GF, Pradilla G, et al. Galbraith Award: simvastatin attenuates experimental cerebral vasospasm and ameliorates serum markers of neuronal and endothelial injury in patients after subarachnoid hemorrhage: a dose-response effect dependent on endothelial nitric oxide synthase. Clin Neurosurg. 2005;52:371–378. [PubMed] [Google Scholar]
  • 40.Lu D, Mahmood A, Goussev A, Qu C, Zhang ZG, Chopp M. Delayed thrombosis after traumatic brain injury in rats. J Neurotrauma. 2004;21:1756–1766. doi: 10.1089/neu.2004.21.1756. [DOI] [PubMed] [Google Scholar]
  • 41.Lu D, Mahmood A, Goussev A, et al. Atorvastatin reduction of intravascular thrombosis, increase in cerebral microvascular patency and integrity, and enhancement of spatial learning in rats subjected to traumatic brain injury. J Neurosurg. 2004;101:813–821. doi: 10.3171/jns.2004.101.5.0813. [DOI] [PubMed] [Google Scholar]
  • 42.Lynch JR, Wang H, McGirt MJ, et al. Simvastatin reduces vasospasm after aneurysmal subarachnoid hemorrhage: results of a pilot randomized clinical trial. Stroke. 2005;36:2024–2026. doi: 10.1161/01.STR.0000177879.11607.10. [DOI] [PubMed] [Google Scholar]
  • 43.Qu C, Lu D, Goussev A, Schallert T, Mahmood A, Chopp M. Effect of atorvastatin on spatial memory, neuronal survival, and vascular density in female rats after traumatic brain injury. J Neurosurg. 2005;103:695–701. doi: 10.3171/jns.2005.103.4.0695. [DOI] [PubMed] [Google Scholar]
  • 44.Lu D, Qu C, Goussev A, et al. Statins increase neurogenesis in the dentate gyrus, reduce delayed neuronal death in the hippocampal CA3 region, and improve spatial learning in rat after traumatic brain injury. J Neurotrauma. 2007;24:1132–1146. doi: 10.1089/neu.2007.0288. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Wu H, Lu D, Jiang H, et al. Increase in phosphorylation of Akt and its downstream signaling targets and suppression of apoptosis by simvastatin after traumatic brain injury. J Neurosurg. 2008;109:691–698. doi: 10.3171/JNS/2008/109/10/0691. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Wu H, Lu D, Jiang H, et al. Simvastatin-mediated upregulation of VEGF and BDNF, activation of the PI3K/Akt pathway, and increase of neurogenesis are associated with therapeutic improvement after traumatic brain injury. J Neurotrauma. 2008;25:130–139. doi: 10.1089/neu.2007.0369. [DOI] [PubMed] [Google Scholar]
  • 47.Chen J, Zhang C, Jiang H, et al. Atorvastatin induction of VEGF and BDNF promotes brain plasticity after stroke in mice. J Cereb Blood Flow Metab. 2005;25:281–290. doi: 10.1038/sj.jcbfm.9600034. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Wang L, Gang Zhang Z, Lan Zhang R, Chopp M. Activation of the PI3-K/Akt pathway mediates cGMP enhanced-neurogenesis in the adult progenitor cells derived from the subventricular zone. J Cereb Blood Flow Metab. 2005;25:1150–1158. doi: 10.1038/sj.jcbfm.9600112. [DOI] [PubMed] [Google Scholar]
  • 49.Horwood JM, Dufour F, Laroche S, Davis S. Signalling mechanisms mediated by the phosphoinositide 3-kinase/Akt cascade in synaptic plasticity and memory in the rat. Eur J Neurosci. 2006;23:3375–3384. doi: 10.1111/j.1460-9568.2006.04859.x. [DOI] [PubMed] [Google Scholar]
  • 50.Chen J, Zhang ZG, Li Y, et al. Statins induce angiogenesis, neurogenesis, and synaptogenesis after stroke. Ann Neurol. 2003;53:743–751. doi: 10.1002/ana.10555. [DOI] [PubMed] [Google Scholar]
  • 51.Weis M, Heeschen C, Glassford AJ, Cooke JP. Statins have biphasic effects on angiogenesis. Circulation. 2002;105:739–745. doi: 10.1161/hc0602.103393. [DOI] [PubMed] [Google Scholar]
  • 52.Hixon ML, Muro-Cacho C, Wagner MW, et al. Akt1/PKB upregulation leads to vascular smooth muscle cell hypertrophy and polyploidization. J Clin Invest. 2000;106:1011–1020. doi: 10.1172/JCI8252. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Narayan RK, Michel ME, Ansell B, et al. Clinical trials in head injury. J Neurotrauma. 2002;19:503–557. doi: 10.1089/089771502753754037. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Rinder L. “Concussive response” and intracranial pressure changes at sudden extradural fluid volume input in rabbits. Acta Physiol Scand. 1969;76:352–360. doi: 10.1111/j.1748-1716.1969.tb04478.x. [DOI] [PubMed] [Google Scholar]
  • 55.Wang H, Gao J, Lassiter TF, et al. Levetiracetam is neuroprotective in murine models of closed head injury and subarachnoid hemorrhage. Neurocrit Care. 2006;5:71–78. doi: 10.1385/NCC:5:1:71. [DOI] [PubMed] [Google Scholar]
  • 56.Lynch JR, Pineda JA, Morgan D, et al. Apolipoprotein E affects the central nervous system response to injury and the development of cerebral edema. Ann Neurol. 2002;51:113–117. doi: 10.1002/ana.10098. [DOI] [PubMed] [Google Scholar]
  • 57.Lynch JR, Wang H, Mace B, et al. A novel therapeutic derived from apolipoprotein E reduces brain inflammation and improves outcome after closed head injury. Exp Neurol. 2005;192:109–116. doi: 10.1016/j.expneurol.2004.11.014. [DOI] [PubMed] [Google Scholar]
  • 58.Zohar O, Schreiber S, Getslev V, Schwartz JP, Mullins PG, Pick CG. Closed-head minimal traumatic brain injury produces long-term cognitive deficits in mice. Neuroscience. 2003;118:949–955. doi: 10.1016/S0306-4522(03)00048-4. [DOI] [PubMed] [Google Scholar]
  • 59.Mahmood A, Goussev A, Lu D, et al. Long-lasting benefits after treatment of traumatic brain injury (TBI) in rats with combination therapy of marrow stromal cells (MSCs) and simvastatin. J Neurotrauma. 2008;25:1441–1447. doi: 10.1089/neu.2007.0495. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 60.McGirt MJ, Lynch JR, Pana A, et al. Simvastatin increases endothelial nitric oxide synthase and ameliorates cerebral vasospasm resulting from subarachnoid hemorrhage. Stroke. 2002;33:2950–2956. doi: 10.1161/01.STR.0000038986.68044.39. [DOI] [PubMed] [Google Scholar]
  • 61.Cheng G, Wei L, Zhi-Dan S, Shi-Guang Z, Xiang-Zhen L. Atorvastatin ameliorates cerebral vasospasm and early brain injury after subarachnoid hemorrhage and inhibits caspase-dependent apoptosis pathway. BMC Neurosci. 2009;10:7–7. doi: 10.1186/1471-2202-10-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 62.Sugawara T, Ayer R, Jadhav V, Chen W, Tsubokawa T, Zhang JH. Simvastatin attenuation of cerebral vasospasm after subarachnoid hemorrhage in rats via increased phosphorylation of Akt and endothelial nitric oxide synthase. J Neurosci Res. 2008;86:3635–3643. doi: 10.1002/jnr.21807. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 63.McGirt MJ, Pradilla G, Legnani FG, et al. Systemic administration of simvastatin after the onset of experimental subarachnoid hemorrhage attenuates cerebral vasospasm. Neurosurgery. 2006;58:945–951. doi: 10.1227/01.NEU.0000210262.67628.7E. [DOI] [PubMed] [Google Scholar]
  • 64.Bulsara KR, Coates JR, Agrawal VK, et al. Effect of combined simvastatin and cyclosporine compared with simvastatin alone on cerebral vasospasm after subarachnoid hemorrhage in a canine model. Neurosurg Focus. 2006;21:E11–E11. doi: 10.3171/foc.2006.21.3.11. [DOI] [PubMed] [Google Scholar]
  • 65.Seyfried D, Han Y, Lu D, Chen J, Bydon A, Chopp M. Improvement in neurological outcome after administration of atorvastatin following experimental intracerebral hemorrhage in rats. J Neurosurg. 2004;101:104–107. doi: 10.3171/jns.2004.101.1.0104. [DOI] [PubMed] [Google Scholar]
  • 66.Jung KH, Chu K, Jeong SW, et al. HMG-CoA reductase inhibitor, atorvastatin, promotes sensorimotor recovery, suppressing acute inflammatory reaction after experimental intracerebral hemorrhage. Stroke. 2004;35:1744–1749. doi: 10.1161/01.STR.0000131270.45822.85. [DOI] [PubMed] [Google Scholar]
  • 67.Prinz V, Laufs U, Gertz K, et al. Intravenous rosuvastatin for acute stroke treatment: an animal study. Stroke. 2008;39:433–438. doi: 10.1161/STROKEAHA.107.492470. [DOI] [PubMed] [Google Scholar]
  • 68.Mayanagi K, Katakam PV, Gaspar T, Domoki F, Busija DW. Acute treatment with rosuvastatin protects insulin resistant (C57BL/6J ob/ob) mice against transient cerebral ischemia. J Cereb Blood Flow Metab. 2008;28:1927–1935. doi: 10.1038/jcbfm.2008.81. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 69.Sironi L, Cimino M, Guerrini U, et al. Treatment with statins after induction of focal ischemia in rats reduces the extent of brain damage. Arterioscler Thromb Vasc Biol. 2003;23:322–327. doi: 10.1161/01.ATV.0000044458.23905.3B. [DOI] [PubMed] [Google Scholar]
  • 70.Naval NS, Abdelhak TA, Zeballos P, Urrunaga N, Mirski MA, Carhuapoma JR. Prior statin use reduces mortality in intracerebral hemorrhage. Neurocrit Care. 2008;8:6–12. doi: 10.1007/s12028-007-0080-2. [DOI] [PubMed] [Google Scholar]
  • 71.Naval NS, Abdelhak TA, Urrunaga N, Zeballos P, Mirski MA, Carhuapoma JR. An association of prior statin use with decreased perihematomal edema. Neurocrit Care. 2008;8:13–18. doi: 10.1007/s12028-007-0081-1. [DOI] [PubMed] [Google Scholar]
  • 72.Leker RR, Khoury ST, Rafaeli G, Shwartz R, Eichel R, Tanne D. Prior use of statins improves outcome in patients with intracerebral hemorrhage: prospective data from the National Acute Stroke Israeli Surveys (NASIS) Stroke. 2009;40:2581–2584. doi: 10.1161/STROKEAHA.108.546259. [DOI] [PubMed] [Google Scholar]
  • 73.FitzMaurice E, Wendell L, Snider R, et al. Effect of statins on intracerebral hemorrhage outcome and recurrence. Stroke. 2008;39:2151–2154. doi: 10.1161/STROKEAHA.107.508861. [DOI] [PubMed] [Google Scholar]
  • 74.Elkind MS, Sacco RL, MacArthur RB, et al. The Neuroprotection with Statin Therapy for Acute Recovery Trial (NeuSTART): an adaptive design phase I dose-escalation study of high-dose lovastatin in acute ischemic stroke. Int J Stroke. 2008;3:210–218. doi: 10.1111/j.1747-4949.2008.00200.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 75.Tseng MY, Czosnyka M, Richards H, Pickard JD, Kirkpatrick PJ. Effects of acute treatment with pravastatin on cerebral vasospasm, autoregulation, and delayed ischemic deficits after aneurysmal subarachnoid hemorrhage: a phase II randomized placebo-controlled trial. Stroke. 2005;36:1627–1632. doi: 10.1161/01.STR.0000176743.67564.5d. [DOI] [PubMed] [Google Scholar]
  • 76.Chou SH, Smith EE, Badjatia N, et al. A randomized, double-blind, placebo-controlled pilot study of simvastatin in aneurysmal subarachnoid hemorrhage. Stroke. 2008;39:2891–2893. doi: 10.1161/STROKEAHA.107.505875. [DOI] [PubMed] [Google Scholar]
  • 77.Vergouwen MD, Meijers JC, Geskus RB, et al. Biologic effects of simvastatin in patients with aneurysmal subarachnoid hemorrhage: a double-blind, placebo-controlled randomized trial. J Cereb Blood Flow Metab. 2009;29:1444–1453. doi: 10.1038/jcbfm.2009.59. [DOI] [PubMed] [Google Scholar]
  • 78.Kerz T, Victor A, Beyer C, Trapp I, Heid F, Reisch R. A case control study of statin and magnesium administration in patients after aneurysmal subarachnoid hemorrhage: incidence of delayed cerebral ischemia and mortality. Neurol Res. 2008;30:893–897. doi: 10.1179/174313208X338034. [DOI] [PubMed] [Google Scholar]
  • 79.Kramer AH, Gurka MJ, Nathan B, Dumont AS, Kassell NF, Bleck TP. Statin use was not associated with less vasospasm or improved outcome after subarachnoid hemorrhage. Neurosurgery. 2008;62:422–430. doi: 10.1227/01.neu.0000316009.19012.e3. [DOI] [PubMed] [Google Scholar]
  • 80.McGirt MJ, Garces Ambrossi GL, Huang J, Tamargo RJ. Simvastatin for the prevention of symptomatic cerebral vasospasm following aneurysmal subarachnoid hemorrhage: a single-institution prospective cohort study. J Neurosurg. 2009;110:968–974. doi: 10.3171/2008.10.JNS08901. [DOI] [PubMed] [Google Scholar]
  • 81.Kern M, Lam MM, Knuckey NW, Lind CR. Statins may not protect against vasospasm in subarachnoid haemorrhage. J Clin Neurosci. 2009;16:527–530. doi: 10.1016/j.jocn.2008.08.001. [DOI] [PubMed] [Google Scholar]
  • 82.Tseng MY, Hutchinson PJ, Turner CL, et al. Biological effects of acute pravastatin treatment in patients after aneurysmal subarachnoid hemorrhage: a double-blind, placebo-controlled trial. J Neurosurg. 2007;107:1092–1100. doi: 10.3171/JNS-07/12/1092. [DOI] [PubMed] [Google Scholar]
  • 83.STASH Trial: SimvaSTatin in Aneurysmal Subarachnoid Hemorrhage. Available at: www.stashtrial.com. Accessed August 18, 2009.
  • 84.Margulies S, Hicks R. Combination therapies for traumatic brain injury: prospective considerations. J Neurotrauma. 2009;26:925–939. doi: 10.1089/neu.2008.0794. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 85.Besson VC, Chen XR, Plotkine M, Marchand-Venecchia C. Fenofibrate, a peroxisome proliferator-activated receptor alpha agonist, exerts neuroprotective effects in traumatic brain injury. Neurosci Lett. 2005;388:7–12. doi: 10.1016/j.neulet.2005.06.019. [DOI] [PubMed] [Google Scholar]
  • 86.Balduini W, Mazzoni E, Carloni S, et al. Prophylactic but not delayed administration of simvastatin protects against long-lasting cognitive and morphological consequences of neonatal hypoxicischemic brain injury, reduces interleukin-1beta and tumor necrosis factor-alpha mRNA induction, and does not affect endothelial nitric oxide synthase expression. Stroke. 2003;34:2007–2012. doi: 10.1161/01.STR.0000080677.24419.88. [DOI] [PubMed] [Google Scholar]
  • 87.Saheki A, Terasaki T, Tamai I, Tsuji A. In vivo and in vitro blood-brain barrier transport of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors. Pharm Res. 1994;11:305–311. doi: 10.1023/A:1018975928974. [DOI] [PubMed] [Google Scholar]
  • 88.Miron VE, Zehntner SP, Kuhlmann T, et al. Statin therapy inhibits remyelination in the central nervous system. Am J Pathol. 2009;174:1880–1890. doi: 10.2353/ajpath.2009.080947. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 89.Amarenco P, Bogousslavsky J, Callahan A, et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006;355:549–559. doi: 10.1056/NEJMoa061894. [DOI] [PubMed] [Google Scholar]
  • 90.Bang OY, Saver JL, Liebeskind DS, et al. Cholesterol level and symptomatic hemorrhagic transformation after ischemic stroke thrombolysis. Neurology. 2007;68:737–742. doi: 10.1212/01.wnl.0000252799.64165.d5. [DOI] [PubMed] [Google Scholar]
  • 91.Blanco M, Nombela F, Castellanos M, et al. Statin treatment withdrawal in ischemic stroke: a controlled randomized study. Neurology. 2007;69:904–910. doi: 10.1212/01.wnl.0000269789.09277.47. [DOI] [PubMed] [Google Scholar]
  • 92.Singhai AB, Topcuoglu MA, Dorer DJ, Ogilvy CS, Carter BS, Koroshetz WJ. SSRI and statin use increases the risk for vasospasm after subarachnoid hemorrhage. Neurology. 2005;64:1008–1013. doi: 10.1212/01.WNL.0000154523.21633.0E. [DOI] [PubMed] [Google Scholar]
  • 93.Menon DK. Unique challenges in clinical trials in traumatic brain injury. Crit Care Med. 2009;37:S129–135. doi: 10.1097/CCM.0b013e3181921225. [DOI] [PubMed] [Google Scholar]
  • 94.Tseng MY, Hutchinson PJ, Czosnyka M, Richards H, Pickard JD, Kirkpatrick PJ. Effects of acute pravastatin treatment on intensity of rescue therapy, length of inpatient stay, and 6-month outcome in patients after aneurysmal subarachnoid hemorrhage. Stroke. 2007;38:1545–1550. doi: 10.1161/STROKEAHA.106.475905. [DOI] [PubMed] [Google Scholar]
  • 95.Montaner J, Chacon P, Krupinski J, et al. Simvastatin in the acute phase of ischemic stroke: a safety and efficacy pilot trial. Eur J Neurol. 2008;15:82–90. doi: 10.1111/j.1468-1331.2007.02015.x. [DOI] [PubMed] [Google Scholar]

Articles from Neurotherapeutics are provided here courtesy of Elsevier

RESOURCES